Phase 2 studies of single-agent cladribine in nonfollicular type NHL
| Study . | Cladribine doses . | Histology . | Previously treated . | Treatment-naive . | Response, % . | Median duration, mo . | |
|---|---|---|---|---|---|---|---|
| OR . | CR . | ||||||
| Dimopoulos et al (1993)57 | A | WM | 20 | 9 | 59 | 3 | > 9 |
| Dimopoulos et al (1994)56 | A | WM | 0 | 26 | 85 | 12 | > 13 |
| Fridrik et al (1997)58 | B | WM | 10 | 0 | 90 | 10 | > 13 |
| Liu et al (1998)59 | B | WM | 13 | 7 | 55 | 5 | > 18 |
| Hellman (1999)60 | C | WM | 13 | 9 | 41 | 36 | 12 (mean) |
| Lefrère et al (2000)55 | A | Splenic MZL | 6 | 1 | 86 | 29 | 4 |
| Jäger et al (2002)54 | B | MZL | 0 | 26 | 100 | 84 | > 32 |
| Rummel et al (1999)53 | D | MCL | 5 | 7 | 58 | 25 | 19 |
| Inwards et al (2008)45 | D | MCL | 24 | 26 | 46 PT; 81 TN | 21 PT; 42 TN | PT: 5; TN: 14 |
| Study . | Cladribine doses . | Histology . | Previously treated . | Treatment-naive . | Response, % . | Median duration, mo . | |
|---|---|---|---|---|---|---|---|
| OR . | CR . | ||||||
| Dimopoulos et al (1993)57 | A | WM | 20 | 9 | 59 | 3 | > 9 |
| Dimopoulos et al (1994)56 | A | WM | 0 | 26 | 85 | 12 | > 13 |
| Fridrik et al (1997)58 | B | WM | 10 | 0 | 90 | 10 | > 13 |
| Liu et al (1998)59 | B | WM | 13 | 7 | 55 | 5 | > 18 |
| Hellman (1999)60 | C | WM | 13 | 9 | 41 | 36 | 12 (mean) |
| Lefrère et al (2000)55 | A | Splenic MZL | 6 | 1 | 86 | 29 | 4 |
| Jäger et al (2002)54 | B | MZL | 0 | 26 | 100 | 84 | > 32 |
| Rummel et al (1999)53 | D | MCL | 5 | 7 | 58 | 25 | 19 |
| Inwards et al (2008)45 | D | MCL | 24 | 26 | 46 PT; 81 TN | 21 PT; 42 TN | PT: 5; TN: 14 |
MZL indicates marginal zone lymphoma; PT, previously treated; and TN, treatment-naive.
A indicates 0.1 mg/kg per day as continuous intravenous infusion for 7 days; B, 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days; C, 0.14 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days; and D, 5 mg/m2 2-hour intravenous infusion for 5 consecutive days.